Contracts › 75N93020C00018
75N93020C00018: To Select a Novel Small Molecule Antibiotic for Clinical Development and Advance It Through Ind Filing and Phase 1 Clinical Studies.
Awarded to Revagenix Inc by National Institutes of Health (NIH).
$26.9Mobligated
$33.9Mpotential value
31 August 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93020C00018 |
|---|---|
| Awardee | Revagenix Inc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | CA |
| Offers received | 12 |
| Period of performance | 01 July 2020 to 31 August 2026 |
| Potential end | 31 October 2026 |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record